Holen Sie sich die Stockscreener-App
16.37
6.24%
-1.09
Handel nachbörslich:
16.37
Lyell Immunopharma Inc Aktie (LYEL) Neueste Nachrichten
Down 33.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Lyell Immunopharma (LYEL) - MSN
Lyell Immunopharma stock (US55083R1041): Analyst boosts price target as cell therapy pipeline advanc - AD HOC NEWS
ARCH funds and directors disclose shared control of 3.25M LYEL shares (LYEL) - Stock Titan
Lyell Immunopharma (LYEL) Slips -6.23%, Testing $16.95 Support 2026-05-15Crowd Breakout Signals - newser.com
Lyell Immunopharma (LYEL) Delivers Q1 2026 Beat — EPS $-1.10 vs $-2.41 ExpectedOperating Margin - Newser
LYEL Earning Date, Earning Analysis and Earning Prediction - Intellectia AI
Lyell Immunopharma to Participate in Investor Conferences During May - geneonline.com
Lyell Immunopharma Announces Participation in May Investor Conferences | Associated Press | syndication news - Enidnews.com
Cancer cell therapy firm Lyell offers investor talks online May 19–20 - Stock Titan
TradingKey - TradingKey
Lyell Immunopharma (LYEL) entities each report 4.3% ownership in amended 13G - Stock Titan
Lyell Immunopharma (NASDAQ:LYEL) Upgraded to Hold at Wall Street Zen - MarketBeat
Explore Investments/Jeff Bezos report 6.6% stake in Lyell (LYEL) - Stock Titan
Lyell Records $24 Mln Loss In Q1, Provides Updates On CAR-T Cell Therapies For Cancer Treatment - RTTNews
Lyell Immunopharma: Q1 Earnings Snapshot - theheraldreview.com
Lyell starts Phase 3 lymphoma dosing, says cash runway reaches Q3 2027 - Stock Titan
Lyell Immunopharma (NASDAQ: LYEL) cuts quarterly loss and raises equity capital - Stock Titan
Lyell Immunopharma (NASDAQ: LYEL) trims Q1 loss and advances CAR T trials - Stock Titan
BRIEF-Lyell Immunopharma Q1 Net Income USD -24.153 Million - TradingView
Lyell Immunopharma Reports Business Highlights and Financial Results for the First Quarter 2026 - GlobeNewswire
Lyell Immunopharma (LYEL) to Release Quarterly Earnings on Tuesday - MarketBeat
Lyell Immunopharma (LYEL) Price Target Increased by 27.27% to 14.28 - MSN
LYEL SEC FilingsLyell Immunopharma, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
BofA Securities Maintains Lyell Immunopharma(LYEL.US) With Sell Rating, Maintains Target Price $12 - Moomoo
Lyell Immunopharma (NASDAQ:LYEL) Upgraded by Robert W. Baird to Strong-Buy Rating - MarketBeat
Lyell Immunopharma (NASDAQ:LYEL) Downgraded to Sell Rating by Wall Street Zen - MarketBeat
Baird initiates Lyell Immunopharma stock with outperform rating By Investing.com - Investing.com South Africa
Baird initiates Lyell Immunopharma stock with outperform rating - Investing.com
Baird Maintains Lyell Immunopharma(LYEL.US) With Buy Rating, Maintains Target Price $49 - Moomoo
BofA reiterates Lyell Immunopharma stock Underperform on rival exit By Investing.com - Investing.com Canada
BofA reiterates Lyell Immunopharma stock Underperform on rival exit - Investing.com
Baird Initiates Lyell Immunopharma(LYEL.US) With Buy Rating, Announces Target Price $49 - Moomoo
Lyell Immunopharma climbs after reporting strong CAR T-cell therapy results - MSN
[ARS] Lyell Immunopharma, Inc. SEC Filing - Stock Titan
Lyell Immunopharma (NASDAQ: LYEL) outlines 2026 virtual meeting, board elections and pay vote - Stock Titan
Lyell Immunopharma (NASDAQ:LYEL) Shares Gap DownHere's What Happened - MarketBeat
LYEL (Lyell Immunopharma Inc.) reports far wider than expected Q4 2025 loss as shares tick modestly higher.Pro Level Trade Signals - Cổng thông tin điện tử tỉnh Tây Ninh
Euler Fund (NASDAQ: LYEL) holds 1,426,528 shares, 6.71% stake disclosed - Stock Titan
Lyell Immunopharma (LYEL) Stock: Gaining Traction? (Underperforming) 2026-04-20Retail Money Flow - UBND thành phố Hải Phòng
Lyell Immunopharma (NASDAQ:LYEL) Upgraded by Wall Street Zen to "Hold" Rating - MarketBeat
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Sees Large Increase in Short Interest - MarketBeat
LYEL Earnings History & Surprises | EPS & Revenue Results | LYELL IMMUNOPHARMA INC (NASDAQ:LYEL) - ChartMill
A First Look At Lyell Immunopharma (NASDAQ:LYEL) - Seeking Alpha
[EFFECT] Lyell Immunopharma, Inc. SEC Filing - Stock Titan
Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel - The Manila Times
Lyell Immunopharma (NASDAQ:LYEL) Shares Down 4%Should You Sell? - MarketBeat
Lyell Immunopharma (NASDAQ:LYEL) Stock Price Up 6.9%Should You Buy? - MarketBeat
This WhiteFiber Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday - Sahm
Needham initiates coverage of Lyell Immunopharma (LYEL) with buy recommendation - MSN
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
0.98%
0.12%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):